DERM Stock Forecast & Price Target

Journey Medical is attractive because Emrosi is showing a clear volume-and-ASP inflection, with 2Q26 net revenue of $8.1M, about 36,000 prescriptions, and more than 4,500 unique prescribers, while quality commercial coverage rose to ~38% from 34% in 1Q26. The company also delivered its first-ever positive GAAP operating income of $0.5M and third consecutive quarter of positive adjusted EBITDA, signaling improving operating leverage as 2Q26 revenue reached $18.5M and gross margin held at 67%. Even after lowering estimates to reflect a more measured ramp, IQVIA prescription trends remain supportive, and expanding formularies, better reimbursement, and a larger addressable prescriber base underpin the long-term outlook.

Journey Medical is facing weakening near-term fundamentals as IQVIA shows 3Q26 prescriptions declining 0.7% sequentially for Qbrexza and 12.9% for Accutane, prompting revenue cuts to $21.0M and $12.5M, respectively. The deterioration in revenue conversion, alongside management’s 2Q26 commentary on payer and patient mix, suggests that earnings leverage is being delayed rather than delivered, with 2026 EPS now estimated at $(0.29) versus $(0.06) previously and 2027 EPS at $0.15 versus $1.07. The negative outlook is further reinforced by competitive pressure in largely genericized markets, reimbursement and regulatory risks, and the possibility that capital needs rise if cash burn exceeds projections.